Treatment of Chronic Tension-Type Headache with Botulinum Toxin: A Double-Blind, Placebo-Controlled Clinical Trial

Cephalalgia

Volumn 25, Issue 11, 2005, Pages 1101-

  Boudreau, G ^a  

^a Clinique Migraine Val Des Arbres   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; CALCITONIN GENE RELATED PEPTIDE;

CLINICAL TRIAL; HUMAN; LETTER; SENSORY NERVE CELL; TENSION HEADACHE; TRIGEMINAL NERVE;

BOTULINUM TOXIN TYPE A; CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMANS; TENSION-TYPE HEADACHE;

EID: 27444437810     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.00990_1.x     Document Type: Letter

References (5)

1. Padberg M Bruijn SFTM de Haan RJ Tavy DLJ. Treatment of chronic tension-type headache with botulinum toxin: a double blind, placebo-controlled clinical trial. Cephalalgia 2004; 24: 675–80.
2. Ashina M. Review on the neurobiology of chronic tension-type headache. Cephalalgia 2004; 24: 161–72.
3. Durham PI Cady R Cady R. The regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implication for migraine therapy. Headache 2004; 44: 35–43.
4. Evers S Rahmann A Vollmer-Haase J Husstedt I-W. Treatment of headached with botulinum toxin A – a review according to evidence-based medecine criteria. Cephalalgia 2002; 22: 699–710.
5. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003; 43: 853–60.